NAT2 gene polymorphism: covert drug interaction causing phenytoin toxicity

被引：7

作者：

Adithan, C. ^{[1
,2
]}

Subathra, A. ^{[3
]}

机构：

[1] Mahatma Gandhi Med Coll & Res Inst, Cent Interdisciplinary Res Facil, Pillaiyarkuppam 607403, Puducherry, India

[2] Mahatma Gandhi Med Coll & Res Inst, Dept Pharmacol, Pillaiyarkuppam 607403, Puducherry, India

[3] JIPMER, Dept Radiodiag, Pondicherry 605006, India

来源：

INDIAN JOURNAL OF MEDICAL RESEARCH | 2016年 / 143卷

关键词：

INDUCED LIVER-INJURY; METABOLIZING-ENZYMES; GENOTYPE; TUBERCULOSIS; ACETYLATION; INHIBITION; THERAPY;

D O I：

10.4103/0971-5916.187101

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

071005 [微生物学]; 100108 [医学免疫学];

摘要：

引用

页码：542 / 544

页数：3

共 23 条

[1]

N-acetyltransferase 2 (NAT2) gene polymorphism as a predisposing factor for phenytoin intoxication in tuberculous meningitis or tuberculoma patients having seizures - A pilot study [J].

Adole, Prashant S. ;

Kharbanda, Parampreet S. ;

Sharma, Sadhna .

INDIAN JOURNAL OF MEDICAL RESEARCH, 2016, 143 :581-590

[2]

Phenotypic interaction of simultaneously administered isoniazid and phenytoin in patients with tuberculous meningitis or tuberculoma having seizures [J].

Adole, Prashant S. ;

Singh, Amandeep ;

Kharbanda, Parampreet S. ;

Sharma, Sadhna .

EUROPEAN JOURNAL OF PHARMACOLOGY, 2013, 714 (1-3) :157-162

[3]

NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: A randomized controlled trial for pharmacogenetics-based therapy [J].

Azuma, Junichi ;

Ohno, Masako ;

Kubota, Ryuji ;

Yokota, Soichiro ;

Nagai, Takayuki ;

Tsuyuguchi, Kazunari ;

Okuda, Yasuhisa ;

Takashima, Tetsuya ;

Kamimura, Sayaka ;

Fujio, Yasushi ;

Kawase, Ichiro .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 69 (05) :1091-1101

[4]

Pharmacogenetics of the arylamine N-acetyltransferases [J].

Butcher N.J. ;

Boukouvala S. ;

Sim E. ;

Minchin R.F. .

The Pharmacogenomics Journal, 2002, 2 (1) :30-42

[5]

Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: Potent inhibition of CYP2C19 and CYP3A [J].

Desta, Z ;

Soukhova, NV ;

Flockhart, DA .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (02) :382-392

[6]

Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole, and ticlopidine [J].

Giancarlo, GM ;

Venkatakrishnan, K ;

Granda, BW ;

von Moltke, LL ;

Greenblatt, DJ .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 57 (01) :31-36

[7]

THE RELATIONSHIP BETWEEN THE ACETYLATOR AND THE SPARTEINE HYDROXYLATION POLYMORPHISMS [J].

HARMER, D ;

EVANS, DAP ;

EZE, LC ;

JOLLY, M ;

WHIBLEY, EJ .

JOURNAL OF MEDICAL GENETICS, 1986, 23 (02) :155-156

[8]

Hein DW, 2000, CANCER EPIDEM BIOMAR, V9, P29

[9]

HUGHES HB, 1954, AM REV TUBERC PULM, V70, P266

[10]

HVIDBERG E F, 1976, Clinical Pharmacokinetics, V1, P161, DOI 10.2165/00003088-197601030-00001

← 1 2 3 →